These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15274762)

  • 1. [Analysis of the effectiveness and costs of amlodipine on the hospitalizations for cardiovascular events in patients with ischemic cardiopathy].
    Galduf Cabañas J; Cosín Aguilar J; Rodríguez-Padialc L; Zamorano Gómez JL; Fernández González I; Rejas Gutiérrrez J
    Rev Clin Esp; 2004 Aug; 204(8):398-404. PubMed ID: 15274762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost analysis of amlodipine versus enalapril in patients with coronary artery disease and normal blood pressure: findings from the CAMELOT economic substudy.
    Menzin J; Boulanger L; Tang S; Thakker K; Nissen SE
    Appl Health Econ Health Policy; 2008; 6(2-3):157-62. PubMed ID: 19231908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacoeconomic impact of amlodipine use on coronary artery disease.
    De Portu S; Menditto E; Scalone L; Bustacchini S; Cricelli C; Mantovani LG
    Pharmacol Res; 2006 Aug; 54(2):158-63. PubMed ID: 16814560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.
    Nissen SE; Tuzcu EM; Libby P; Thompson PD; Ghali M; Garza D; Berman L; Shi H; Buebendorf E; Topol EJ;
    JAMA; 2004 Nov; 292(18):2217-25. PubMed ID: 15536108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospital use and costs among patients with nonischemic cardiomyopathy in the first prospective randomized amlodipine survival evaluation study.
    O'Connor CM; Radensky PW; Unger AN; Martin BC
    Clin Ther; 1999 Jul; 21(7):1254-65. PubMed ID: 10463522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension.
    Doyle J; Omvik P; Arikian S; Casciano J; Casciano R; Gonzalez MA; Arocho R
    Manag Care Interface; 2001 Mar; 14(3):82-7. PubMed ID: 11301961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic benefits of amlodipine treatment in patients with coronary artery disease.
    Casciano R; Doyle JJ; Chen J; Arikian S; Casciano J; Kugel H; Arocho R
    Pharmacoeconomics; 2002; 20(8):553-63. PubMed ID: 12109920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Bilous RW
    J Hum Hypertens; 2004 Oct; 18(10):733-8. PubMed ID: 15116142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomic consequences of amlodipine besylate therapy in patients undergoing PTCA.
    Rossetti F; De Portu S; Menditto E; Scalone L; Bustacchini S; Cricelli C; Mantovani LG
    Pharmacol Res; 2006 Mar; 53(3):197-201. PubMed ID: 16406672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmacoeconomic evaluation of results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES) in Norway and Canada.
    Thaulow E; Jorgensen B; Doyle JJ; Casciano R; Casciano J; Kopp Z; Arikian S; Kim R
    Int J Cardiol; 2002 Jul; 84(1):23-30; discussion 30-2. PubMed ID: 12104059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-effectiveness evaluation of amlodipine usage in patients with coronary artery disease in Sweden.
    Doyle JJ; McGuire A; Arocho R; Arikian S; Casciano J; Svangren P; Casciano R; Kim R; Kugel H
    Int J Clin Pract; 2002 Mar; 56(2):76-81. PubMed ID: 11926709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
    Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
    Heart; 2008 Feb; 94(2):e4. PubMed ID: 17916665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
    Berl T; Hunsicker LG; Lewis JB; Pfeffer MA; Porush JG; Rouleau JL; Drury PL; Esmatjes E; Hricik D; Parikh CR; Raz I; Vanhille P; Wiegmann TB; Wolfe BM; Locatelli F; Goldhaber SZ; Lewis EJ;
    Ann Intern Med; 2003 Apr; 138(7):542-9. PubMed ID: 12667024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of the budget impact for the Spanish National Health System of the fixed combination of amlodipine 5 or 10mg and atorvastatin 10mg].
    De Salas M; Fernández De Bobadilla J; Ferro B; Rejas J
    Farm Hosp; 2010; 34(4):170-80. PubMed ID: 20382552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study.
    Björholt I; Andersson FL; Kahan T; Ostergren J
    J Intern Med; 2002 Jun; 251(6):508-17. PubMed ID: 12028506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of nisoldipine ER and amlodipine for the treatment of mild to moderate hypertension.
    Whitcomb C; Enzmann G; Pershadsingh HA; Johnson R; Ciuryla V; Reisin E
    Int J Clin Pract; 2000 Oct; 54(8):509-13. PubMed ID: 11198728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effectiveness and safety of low cost versus innovator brand amlodipine in hypertension: A single-blinded, randomized, crossover, noninferiority trial.
    Das AK; Chatterjee S; Pal J
    Indian J Pharmacol; 2016; 48(6):706-709. PubMed ID: 28066111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.